<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7052542\results\search\drugs\results.xml">
  <result pre="in the neuraminidase and M2 genes that confer resistance to" exact="oseltamivir" post="and adamantanes were assessed. Fatal and nonfatal cases were"/>
  <result pre="increasing viral RNA loads on admission. Furthermore, the prevalence of" exact="amantadine" post="resistance–conferring M2 mutations increased over time, and viral loads"/>
  <result pre="(80%) and particularly in blood (85%), and antiviral responses to" exact="oseltamivir" post="appeared less pronounced. Conclusions These observations confirm the association"/>
  <result pre="and suggest potential differences in virulence and antiviral responses to" exact="oseltamivir" post="that may explain the exceptionally high mortality related to"/>
  <result pre="point to potential differences in virulence and antiviral responses to" exact="oseltamivir" post="that may explain the exceptionally high mortality related to"/>
  <result pre="loads, the presence of viremia, and a poor response to" exact="oseltamivir" post="treatment due to antiviral resistance [7–13]. Comparable data from"/>
  <result pre="detected in blood, and early antiviral responses to treatment with" exact="oseltamivir" post="appeared less pronounced when compared to Vietnamese H5N1 clade"/>
  <result pre="neuraminidase and matrix 2 (M2) genes that confer resistance to" exact="oseltamivir" post="and adamantanes, respectively, was analyzed using pyrosequencing or Sanger"/>
  <result pre="Figure 3). Figure 3. Viral RNA load and prevalence of" exact="amantadine" post="resistance over time. A, H5N1 RNA levels in admission"/>
  <result pre="of infection. Median value indicated in red. B, Prevalence of" exact="amantadine" post="resistance-conferring M2 mutations over time. Viral RNA was also"/>
  <result pre="respectively; P = .08). Response to Antiviral Treatment Treatment with" exact="oseltamivir" post="had a statistically significant impact on clinical outcome: 22"/>
  <result pre="days 4 and 5. Figure 4. Viral RNA load during" exact="oseltamivir" post="treatment. A, H5N1 RNA levels in serial throat swabs"/>
  <result pre="(black line) and surviving (dashed line) cases before and during" exact="oseltamivir" post="treatment. B, Changes in H5N1 RNA load from pretreatment"/>
  <result pre="red. Oseltamivir and Adamantane Resistance Mutations The presence of the" exact="oseltamivir" post="resistance–conferring His275Tyr (H275Y) substitution in neuraminidase (NA) was investigated"/>
  <result pre="168 pharyngeal samples collected from 78 patients after initiation of" exact="oseltamivir" post="treatment (Supplementary Table 1) and was not observed in"/>
  <result pre="contributed to the higher mortality among Indonesian patients. Treatment with" exact="oseltamivir" post="was associated with a survival benefit. This benefit was"/>
  <result pre="vs 18%), despite late treatment initiation in both [21]. Common" exact="oseltamivir" post="resistance–conferring neuraminidase mutations, including H275Y, R293K, and N295S [18],"/>
  <result pre="a range of other neuraminidase mutations reportedly associated with reduced" exact="oseltamivir" post="susceptibility in recently published whole-genome, next-generation sequencing data that"/>
  <result pre="known resistance mutations to explain the apparent limited benefit of" exact="oseltamivir" post="treatment in Indonesian patients. However, in vitro susceptibility testing"/>
  <result pre="2.1 viruses are intrinsically up to 30-fold less susceptible to" exact="oseltamivir" post="than clade 1 viruses [27]. Similar differences in oseltamivir"/>
  <result pre="to oseltamivir than clade 1 viruses [27]. Similar differences in" exact="oseltamivir" post="susceptibility between human seasonal influenza A and B viruses"/>
  <result pre="in Indonesian patients that show that, despite an absence of" exact="oseltamivir" post="resistance mutations, viral RNA was still detectable after 2"/>
  <result pre="limited, this might be explained by the aforementioned differences in" exact="oseltamivir" post="susceptibility. Changes in mortality were observed during the study"/>
  <result pre="in mice infected with isogenic recombinant H1N1 viruses that harbored" exact="amantadine" post="resistance mutations (Val27Ala, Ser31Gly, or both) was higher than"/>
  <result pre="29.KawaiN, IkematsuH, IwakiN, et al.A comparison of the effectiveness of" exact="oseltamivir" post="for the treatment of influenza A and influenza B:"/>
  <result pre="BoivinGGeneration and characterization of recombinant influenza A (H1N1) viruses harboring" exact="amantadine" post="resistance mutations. Antimicrob Agents Chemother2005; 49:556–9.15673732 33.PizzornoA, BouhyX, AbedY,"/>
  <result pre="neuraminidase inhibitors. J Infect Dis2011; 203:25–31.21148493 34.GrambasS, BennettMS, HayAJInfluence of" exact="amantadine" post="resistance mutations on the pH regulatory function of the"/>
 </snippets>
</snippetsTree>
